The latest data point for ABBV's Operation Income in Q1'26 shows a robust $4.73B, marking a sequential increase from $4.54B in Q4'25 and reflecting continued positive momentum in the pharmaceutical sector. This figure represents a year-over-year growth of 26.8%, underscoring operational resilience amid market challenges. Over the period from Q2'23 to Q1'26, Operation Income has exhibited volatility with an overall upward trend, fluctuating between a low of -$1.49B in Q4'24 and highs near $4.89B in Q2'25. Key patterns include sharp declines in Q3'23 (-50.4% YoY) and Q4'24 (-146.6% YoY), likely due to one-time charges or cost pressures, followed by strong recoveries such as the 404.9% YoY surge in Q4'25. The bar chart highlights inconsistent quarterly performance, while the overlaid YoY line indicates improving growth in recent periods, with positive changes in six of the last eight quarters averaging 25.8%.